Trellis Bioscience Information

Trellis Bioscience is a private, venture-funded therapeutic antibody company focusing on the development of three human monoclonal antibodies for the treatment of infectious diseases, all of which are at a similar stage in drug development with expected IND filings in 2018. The Company was formed around a breakthrough discovery platform (CellSpot™)capable of isolating therapeutic grade antibodies directly from the blood cells of humans. CellSpot™ uses computerized microscopy to drastically miniaturize a multiplexed antigen binding assay capable of screening millions of individual antibody producing B cells. In addition to developing a portfolio of human antibodies for the treatment of infectious diseases, Trellis has a portfolio of high-affinity human mAbs against cancer antigens and immune checkpoint inhibitor proteins, such as TIM-3 and KIR, all of which were isoltaed from heathly individuals. Trellis is also engaged in studying anti-drug antibodies (ADAs) for pharmaceutical partners. Funding for the RSV and Biofilm programs has been received from US National Institute of Allergy and Infectious Diseases (grants R44AI122360, R44AI120425, and SB1AI120425).